Today: 7 February 2026
Subscribe
Browse Category

Health News News 18 December 2025 - 2 February 2026

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
25 January 2026
·····
Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly shares rose 0.5% to $1,038.40 Friday, ahead of a holiday-shortened week. Traders are watching early U.S. prescription numbers for Novo Nordisk’s new oral Wegovy, which logged 3,071 scripts in its debut, just below Lilly’s Zepbound. U.S. markets reopen Tuesday, with investors eyeing fresh demand signals and pricing risks. About 3.8 million Lilly shares traded Friday.
19 January 2026
···
Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

ImmunityBio shares jumped 16.5% to $4.60 Friday after the company reported $113 million in preliminary 2025 net product revenue from ANKTIVA and disclosed accelerated approvals in Saudi Arabia for lung and bladder cancer uses. Trading volume topped 56 million shares. Enrollment in the company’s pivotal bladder-cancer trial surpassed 85%, with FDA filing planned by late 2026.
16 January 2026
···
Costco Canada recall expands: Peace by Chocolate pistachio chocolates pulled over salmonella risk

Costco Canada recall expands: Peace by Chocolate pistachio chocolates pulled over salmonella risk

Costco Canada recalled certain Peace by Chocolate gift boxes sold online after a supplier warned of possible Salmonella in two pistachio chocolates. The recall affects products bought on Costco.ca between Sept. 7 and Dec. 3, with no reported illnesses as of Jan. 8. Canada’s pistachio recall list now covers over 330 products. The CFIA says its investigation is ongoing and more recalls may follow.
9 January 2026
·
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck shares slipped 0.2% in after-hours trading after U.S. health officials cut HPV vaccine guidance to one dose, raising concerns over Gardasil sales. Analysts warned the change could reduce 2026 Gardasil revenue by up to $630 million. Merck also completed its $9.2 billion Cidara acquisition and set Feb. 3 for quarterly results.
8 January 2026
····
Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk’s U.S.-listed shares rose 4.7% to $57.71 Tuesday after launching oral Wegovy for self-pay patients at $149 a month for starter doses. The pill is now available at major pharmacies and through telehealth. Investors await early demand data and updates from a key healthcare conference on Jan. 13. Rival Eli Lilly expects a regulatory decision on its own weight-loss pill in March.
6 January 2026
···
Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk’s U.S.-listed shares rose about 4% in premarket trading after the company launched an oral version of its Wegovy weight-loss drug, priced from $149 a month for some cash-paying patients. The stock traded at $57.29, up from $55.11. Investors are watching early demand and await the company’s February 4 results for margin outlook. The launch comes amid restructuring and job cuts at Novo’s U.S. operations.
6 January 2026
···
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics shares fell 9.9% to $31.93 Monday after Novo Nordisk launched its Wegovy weight-loss pill in the U.S. with starter doses priced at $149 per month for cash-pay patients. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly dropped 3.9%. Viking’s next updates include Phase 3 trial milestones in Q1 and an earnings release expected Feb. 4.
5 January 2026
·····
Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals shares fell 6.9% to $63.11 Monday after Health Canada approved Redemplo, its triglyceride-lowering drug for familial chylomicronemia syndrome. The stock dropped despite the clearance, tracking weakness across biotech stocks. Investors now await Arrowhead’s obesity data webinar on Jan. 6 and its J.P. Morgan conference presentation Jan. 12.
5 January 2026
···
Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics Inc. (NASDAQ: GPCR) is ending 2025 in the middle of one of biotech’s hottest battlegrounds: oral weight-loss medicines. As of Dec. 23, 2025, GPCR shares were trading around $67.50 in U.S. session data, after a volatile stretch driven by blockbuster obesity-trial headlines, a major equity financing, and a wave of analyst price-target updates. Below is a comprehensive roundup of the latest news, forecasts, and analysis available as of 23.12.2025, and what investors are watching next. What is Structure Therapeutics, and why does GPCR trade like a headline detector? Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule
23 December 2025
····
FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

On December 22, 2025, Novo Nordisk won one of the most consequential regulatory decisions in modern obesity medicine: U.S. FDA approval of a once‑daily “Wegovy pill” (oral semaglutide 25 mg) for chronic weight management—marking the first oral GLP‑1 authorized in the U.S. specifically for weight loss. Novo Nordisk+1 For Novo Nordisk, the milestone is more than a product expansion. It’s a high‑stakes move to defend its GLP‑1 franchise, widen access beyond injections, and reassert momentum after a volatile year in which investors questioned its growth trajectory and competitive positioning. Reuters+1 What the FDA approved on December 22, 2025 The Wegovy
23 December 2025
··
So Delicious Dairy Free Ice Cream Recall: Danone Pulls Salted Caramel Cluster Pints Over Possible “Small Stones” (Dec. 17, 2025)

So Delicious Dairy Free Ice Cream Recall: Danone Pulls Salted Caramel Cluster Pints Over Possible “Small Stones” (Dec. 17, 2025)

December 17, 2025 — If you keep dairy-free frozen treats stocked for the holidays, it’s worth taking a quick look in your freezer. Danone U.S. has issued a voluntary nationwide recall for specific pints of So Delicious Dairy Free Salted Caramel Cluster after the company warned the product may contain foreign materials — including small stones and other hard objects — in the cashew pieces mixed into the dessert. U.S. Food and Drug Administration+1 The recall, which was posted by the U.S. Food and Drug Administration (FDA) as a company announcement, applies to a single So Delicious flavor and pint
18 December 2025
·
1 2 3

Stock Market Today

Agricultural Bank of China 601288 A-shares slide as tech rout bites; inflation data is the next test

Agricultural Bank of China 601288 A-shares slide as tech rout bites; inflation data is the next test

7 February 2026
Agricultural Bank of China’s A shares closed down 0.45% at 6.67 yuan in Shanghai Friday, with turnover at 2.24 billion yuan. The bank’s A-share capital remained unchanged at 319.24 billion shares as of Jan. 31. Mainland and Hong Kong stocks fell after a global tech selloff and a sharp drop in silver futures. China’s January CPI data is due Feb. 11, with trading expected to thin ahead of the Lunar New Year break.
Palantir stock price rebounds after AI shakeout — what traders watch next week

Palantir stock price rebounds after AI shakeout — what traders watch next week

7 February 2026
Palantir Technologies shares rose 4.5% to $135.90 Friday after reporting a 70% jump in Q4 revenue to $1.407 billion and forecasting 61% revenue growth in 2026. The stock rebounded from a 6.8% drop Thursday, triggered by concerns over Big Tech capital spending and AI’s impact on software demand. A new partnership with Cognizant and U.S. government policy shifts kept Palantir in focus. Director Alexander D. Moore sold 20,000 shares on Feb. 2.
Coca-Cola stock price ends near $79 — frozen products exit sets up KO earnings week

Coca-Cola stock price ends near $79 — frozen products exit sets up KO earnings week

7 February 2026
Coca-Cola will discontinue its frozen products, including the Minute Maid frozen line, in the U.S. and Canada in Q1 2026. Shares closed Friday up 0.66% at $79.03 ahead of Tuesday’s quarterly results. CEO James Quincey sold 337,824 shares on Feb. 3 for about $26 million under a pre-arranged plan. Options pricing suggests a possible 3% move after earnings.
Go toTop